Arbutus Biopharma
ABUS
ABUS
55 hedge funds and large institutions have $29.7M invested in Arbutus Biopharma in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 22 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
55
Holders Change
-7
Holders Change %
-11.29%
% of All Funds
1.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
10
Reduced
22
Closed
14
Calls
–
Puts
$8K
Net Calls
-$8K
Net Calls Change
+$16K
Top Buyers
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
51
Squarepoint
New York
| – | -$137K | -65,848 | Closed |
|
52
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$129K | -57,000 | Closed |
|
53
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$64K | -30,593 | Closed |
|
|
VF
54
Virtu Financial
New York
| – | -$51K | -24,548 | Closed |
|
55
D.E. Shaw & Co
New York
| – | -$40K | -19,300 | Closed |
|
56
Citadel Advisors
Miami,
Florida
| – | -$25K | -11,959 | Closed |
|
57
Legal & General Group
London,
United Kingdom
| – | -$11K | -5,247 | Closed |
|
|
AG
58
Aperio Group
Sausalito,
California
| – | -$3K | -1,234 | Closed |
|
|
PCP
59
Proficio Capital Partners
Newton,
Massachusetts
| – | -$1K | -495 | Closed |
|